Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISHL HL Update 2021 | Novel approaches in HL

Paul Jan Bröckelmann • 11 Mar 2021
ISHL HL Update 2021
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin Nivolumab Pembrolizumab

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, explores the next steps in the treatment and management of Hodgkin lymphoma, including the development of second-generation anti-PD-1 antibodies, CD30-targeting CAR T-cell therapies, as well as combination strategies investigated in relapsed/refractory HL patients. Dr Bröckelmann also touches on areas of unmet needs in HL, including the treatment of older HL patients, the importance of identifying response biomarkers as well as rational combination strategies. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.

More from Paul Jan Bröckelmann

The growing role of anti-PD1 inhibitors in the frontline treatment of HL
2:32
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann • 17 Oct 2022
The importance of individualizing treatment approaches in HL to improve patient outcomes
2:04
The importance of individualizing treatment approaches in HL to improve patient outcomes
Paul Jan Bröckelmann • 17 Oct 2022
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
2:27
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
Paul Jan Bröckelmann • 17 Oct 2022
Recent clinical developments in the treatment landscape for older patients with HL
2:17
Recent clinical developments in the treatment landscape for older patients with HL
Paul Jan Bröckelmann • 17 Oct 2022

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals